SV2018005733A - Procedimientos para el tratamiento y la profilaxis de vih y sida - Google Patents

Procedimientos para el tratamiento y la profilaxis de vih y sida

Info

Publication number
SV2018005733A
SV2018005733A SV2018005733A SV2018005733A SV2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A
Authority
SV
El Salvador
Prior art keywords
treatment
hiv
aids
procedures
prophylaxis
Prior art date
Application number
SV2018005733A
Other languages
English (en)
Spanish (es)
Inventor
Daria Hazuda
Michael D Miller
Jay A Grobler
-Griffith Deborah Anne Nicoli
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SV2018005733A publication Critical patent/SV2018005733A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
SV2018005733A 2016-02-12 2018-08-09 Procedimientos para el tratamiento y la profilaxis de vih y sida SV2018005733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19

Publications (1)

Publication Number Publication Date
SV2018005733A true SV2018005733A (es) 2018-12-14

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005733A SV2018005733A (es) 2016-02-12 2018-08-09 Procedimientos para el tratamiento y la profilaxis de vih y sida

Country Status (37)

Country Link
US (4) US10537589B2 (https=)
EP (1) EP3413897B1 (https=)
JP (4) JP6810972B2 (https=)
KR (4) KR20220126787A (https=)
CN (2) CN113509480A (https=)
AU (3) AU2017217656B2 (https=)
BR (1) BR112018016349A2 (https=)
CA (1) CA3013473C (https=)
CL (1) CL2018002150A1 (https=)
DK (1) DK3413897T3 (https=)
DO (1) DOP2018000183A (https=)
EA (1) EA201891814A1 (https=)
ES (1) ES2953535T3 (https=)
FI (1) FI3413897T3 (https=)
GE (2) GEP20217231B (https=)
HR (1) HRP20230935T1 (https=)
HU (1) HUE063532T2 (https=)
IL (1) IL260874B2 (https=)
JO (1) JOP20170038B1 (https=)
LT (1) LT3413897T (https=)
MD (1) MD3413897T2 (https=)
MX (3) MX390604B (https=)
MY (1) MY197090A (https=)
NI (1) NI201800083A (https=)
NZ (1) NZ745065A (https=)
PH (1) PH12018501712A1 (https=)
PL (1) PL3413897T3 (https=)
PT (1) PT3413897T (https=)
RS (1) RS64448B1 (https=)
SG (1) SG11201806783WA (https=)
SI (1) SI3413897T1 (https=)
SV (1) SV2018005733A (https=)
TN (1) TN2018000267A1 (https=)
TW (2) TWI911551B (https=)
UA (1) UA126375C2 (https=)
WO (1) WO2017139519A1 (https=)
ZA (1) ZA201805073B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
EP3823632B1 (en) * 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
JP7530899B2 (ja) * 2018-12-20 2024-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Nrtti化合物の新規結晶形態
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
AU2020231934B2 (en) * 2019-03-06 2023-04-20 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
WO2021021717A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831852B1 (en) * 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
EA012844B1 (ru) 2003-02-19 2009-12-30 Йельский Университет Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
CN108289931B (zh) 2015-09-23 2022-10-11 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
KR102272235B1 (ko) * 2016-05-12 2021-07-01 머크 샤프 앤드 돔 코포레이션 항바이러스제의 전달을 위한 약물 전달 시스템
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
CA3150272A1 (en) * 2019-08-13 2021-02-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
CA3013473C (en) 2021-10-26
HRP20230935T1 (hr) 2023-11-24
MX2018009763A (es) 2018-11-29
US11337991B2 (en) 2022-05-24
HUE063532T2 (hu) 2024-01-28
US20250073254A1 (en) 2025-03-06
CN113509480A (zh) 2021-10-19
AU2022201686B2 (en) 2024-08-08
JP7559175B2 (ja) 2024-10-01
RS64448B1 (sr) 2023-09-29
AU2020202866A1 (en) 2020-05-21
JP6810972B2 (ja) 2021-01-13
CN108697727A (zh) 2018-10-23
GEAP202014873A (en) 2020-07-27
KR20210049201A (ko) 2021-05-04
TN2018000267A1 (en) 2020-01-16
AU2017217656B2 (en) 2020-01-30
DOP2018000183A (es) 2018-12-31
MD3413897T2 (ro) 2023-11-30
EA201891814A1 (ru) 2019-01-31
JP2021001189A (ja) 2021-01-07
WO2017139519A1 (en) 2017-08-17
IL260874B1 (en) 2023-06-01
US20220331350A1 (en) 2022-10-20
SG11201806783WA (en) 2018-09-27
KR20180108815A (ko) 2018-10-04
PT3413897T (pt) 2023-08-28
MY197090A (en) 2023-05-24
US12171776B2 (en) 2024-12-24
CA3013473A1 (en) 2017-08-17
ES2953535T3 (es) 2023-11-14
ZA201805073B (en) 2019-05-29
AU2020202866B2 (en) 2022-04-07
US10537589B2 (en) 2020-01-21
MX2022002925A (es) 2023-02-10
KR20250136420A (ko) 2025-09-16
LT3413897T (lt) 2023-08-25
NZ784982A (en) 2025-03-28
TWI822652B (zh) 2023-11-21
DK3413897T3 (da) 2023-09-18
HK1257347A1 (en) 2019-10-18
JP2022062170A (ja) 2022-04-19
PH12018501712A1 (en) 2019-05-15
NZ745065A (en) 2023-11-24
US20180055867A1 (en) 2018-03-01
JP7559175B6 (ja) 2024-10-22
JP2024001206A (ja) 2024-01-09
GEP20217231B (en) 2021-03-25
MX390604B (es) 2025-03-20
MX2022002924A (es) 2022-12-15
TWI911551B (zh) 2026-01-11
JOP20170038B1 (ar) 2021-08-17
FI3413897T3 (fi) 2023-08-25
IL260874B2 (en) 2023-10-01
CL2018002150A1 (es) 2018-12-14
NI201800083A (es) 2018-10-05
EP3413897A1 (en) 2018-12-19
IL260874A (https=) 2018-09-20
TW202417010A (zh) 2024-05-01
AU2022201686A1 (en) 2022-03-31
JP2019504857A (ja) 2019-02-21
KR102317570B1 (ko) 2021-10-25
GEP20207190B (en) 2020-12-10
AU2017217656A1 (en) 2018-08-23
PL3413897T3 (pl) 2023-10-02
US20200101098A1 (en) 2020-04-02
SI3413897T1 (sl) 2023-11-30
BR112018016349A2 (pt) 2018-12-26
TW201731514A (zh) 2017-09-16
JP7021314B2 (ja) 2022-02-16
KR20220126787A (ko) 2022-09-16
EP3413897B1 (en) 2023-06-14
UA126375C2 (uk) 2022-09-28

Similar Documents

Publication Publication Date Title
SV2018005733A (es) Procedimientos para el tratamiento y la profilaxis de vih y sida
AR130699A2 (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CA2998646C (en) 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
SV2009003294A (es) Inhibidores de transcriptasa inversa no nucleosidicos
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
MX2024013042A (es) Compuestos para el tratamiento de la infeccion por arenavirus.
AR107596A1 (es) Procedimientos para el tratamiento y la profilaxis de vih y sida
HK40061663A (en) Combination treatment of hiv infections